Skip to content
WSU-DLCL2
Tissue
Pleural effusion
Disease
Diffuse large B-cell lymphoma germinal center B-cell type
Synonyms
WSU-DLCL-2, WSU-DLCL(2), WSUDLCL2

Documents

WSU-DLCL2

Cell line · Product number 305655

WSU-DLCL2 is a human diffuse large B-cell lymphoma (DLBCL) cell line that has been widely used in lymphoma research. It is part of several large-scale gen...

€430.00excl. tax and shipping

Customization / Recommendations

In stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

WSU-DLCL2 is a human diffuse large B-cell lymphoma (DLBCL) cell line that has been widely used in lymphoma research. It is part of several large-scale genomic and proteomic characterization efforts, such as the Cancer Cell Line Encyclopedia (CCLE) and the LL-100 panel, which provide comprehensive molecular data for leukemia and lymphoma models. WSU-DLCL2 is classified within the germinal center B-cell (GCB) subtype of DLBCL and carries the EZH2 Y646F mutation, which is associated with altered histone methylation and epigenetic regulation of gene expression.

This cell line has been included in whole-genome sequencing studies to identify mutational landscapes in DLBCL, revealing a variety of structural alterations, somatic point mutations, and gene fusions. These genomic analyses have contributed to a better understanding of the oncogenic pathways involved in lymphomagenesis. Additionally, studies utilizing protein expression profiling, such as reverse-phase protein arrays, have demonstrated that WSU-DLCL2 exhibits distinct signaling pathway alterations that may influence drug sensitivity.

WSU-DLCL2 has also been studied in the context of antibody-dependent cellular cytotoxicity (ADCC) and resistance to targeted therapies, such as rituximab. Research has shown that the susceptibility of WSU-DLCL2 to rituximab-induced ADCC is influenced by the expression of CD20 and ligands for natural killer (NK) cell receptors, such as UL16-binding proteins (ULBP1-3). These findings support the use of WSU-DLCL2 as a preclinical model for evaluating novel therapeutic strategies targeting DLBCL.

Tissue
Pleural effusion
Disease
Diffuse large B-cell lymphoma germinal center B-cell type
Synonyms
  • WSU-DLCL-2
  • WSU-DLCL(2)
  • WSUDLCL2

02Classification

Organism
Human
Sex
Male
Growth properties
Suspension
Biosafety level
1

03Characteristics

Morphology
Round and oval cells growing singly or in small clumps
Doubling time
18 hours, 40-60 hours

04Identifiers

Citation
WSU-DLCL2 (Cytion catalog number 305655)
NCBI TaxID
9606
Cellosaurus
CVCL_1902

05Expression and susceptibility

Antigen expression
CD3 -, CD10 +, CD13 -, CD19 +, CD20 +, CD34 -, CD37 +, CD38 +, cyCD79a +, CD80 -, CD 138 -, HLA-DR +, sm/cyIgG +, sm/cyIgM -, sm/cykappa -, sm/cylambda +
Mutational profile
Mutation: EZH2, Simple, p.Tyr646Phe (c.1937A>T) (Y641F), Heterozygous, TP53, Simple, p.Arg248Gln (c.743G>A), Homozygous
Viruses
EBV -, HBV -, HCV -, HIV-1 -, HIV-2 -, HTLV-1/2 -, MLV -, SMRV -

06Handling and culture

Culture medium
RPMI 1640, w: 2.1 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
Incubation atmosphere

37°C, 5% CO2, humidified atmosphere.

Supplements
Supplement the medium with h.i.a. 10% FBS
Subculturing
0.5 x 106 cells/ml
Seeding density
3-5*10^5/ml
Fluid renewal
2 to 3 times per week
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Freeze medium
As a cryopreservation medium, we recommend CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

08Donor

Donor age
41 years
Ethnicity
Caucasian

10Product details

Composition table